Drug Approval | December 23, 2025
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The initiative is focused on a problem that continues to plague cancer outcomes in India
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
